<DOC>
	<DOCNO>NCT00704028</DOCNO>
	<brief_summary>The objective study evaluate safety FCM patient anemia dialysis dependent .</brief_summary>
	<brief_title>Safety Tolerability Ferric Carboxymaltose ( FCM ) Versus Iron Dextran Treating Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Subjects ≥18 year age able give inform consent Iron deficiency primary etiology anemia History intolerance unsatisfactory response oral iron Screening Visit central laboratory Hgb ≤11 g/dL Screening Visit ferritin ≤100 ng/mL ≤300 TSAT ≤30 % Previous participation FCM trial Known hypersensitivity reaction FCM iron dextran Requires dialysis treatment chronic kidney disease Current anemia attribute iron deficiency Received IV iron , RBC transfusion ( ) , antibiotic 10 day prior screen phase Anticipated need surgery 30 day period prior screen study period AST ALT great 1.5 time upper limit normal Received investigational drug within 30 day screen Women breastfeed Pregnant sexuallyactive female willing use effective form birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>